Dustan Bonnin

Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products.

Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA.

UCSD Medical Center provides medical services to its clients. The medical center is a part of University of California, San Diego. UCSD Medical Center's facilities consist of UCSD Thornton Hospital in La Jolla, UCSD Medical Center in Hillcrest, and several specialty outpatient clinics and ambulatory health facilities throughout the area. The services provided by the medical center and its affiliates include general medicine and primary care, women's health services, and emergency care for the treatment of serious conditions. The company is headquartered in San Diego, CA